Medicamen Biotech Limited (MBL) has announced that it has entered into an understanding with a prominent South African business conglomerate for registering and marketing its products in the region. South Africa represents a $4 billion pharmaceutical market and is categorized as a regulated market.

The recent EU approval of MBL's plant has opened new avenues to explore such opportunities, aligning with the company's strategic vision of global expansion. The management is confident in leveraging this milestone to further strengthen its presence in regulated markets and drive future growth.